CRISPR Therapeutics (NASDAQ: CRSP) has hired Tony Ho to serve as the company’s executive vice president and head of research and development. Switzerland-based CRISPR Therapeutics, which maintains its R&D operations in Cambridge, MA, is developing therapies based on the CRISPR gene-editing technology. Ho comes to the company from AstraZeneca (NYSE: AZN), where he was senior vice president and head of oncology integration and innovation.
Sponsored · Whitepaper
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting
Sponsored · Whitepaper
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
